SymBio Pharmaceuticals Limited (4582.T)
Tokyo · JPY · Healthcare · Drug Manufacturers - Specialty & Generic
¥47 (+0.00%) as of
Key statistics
- Market cap
- 3.77B
- Forward P/E
- 1.20
- EPS (TTM)
- -96.66
- Dividend yield
- 0.00%
- 52-week range
- 46.00 – 229.00
- Beta
- 0.55
- Revenue (TTM)
- 1.13B
- Profit margin
- 0.00%
- Volume
- 485.80k
About SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; and SyB L-1702, an RI administration under the TREAKISYM name. The company was incorporated in 2005 and is based in Minato, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Minato, Japan
- Employees
- 91
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.